Global Market Size And Competitive Landscape: The Emergency Medical Track Dominated By Teleflex And BD
May 12, 2026
Intraosseous (IO) Access Needles, as life‑saving devices for establishing vascular access in emergency medical scenarios, are witnessing steady growth alongside the improvement of global emergency medical systems and the standardization of pre‑hospital emergency care. According to BIS Research, the global intraosseous device market reached RMB 7.606 billion in 2025, with the Chinese market at RMB 2.356 billion. The global market is projected to reach RMB 10.949 billion by 2032, representing a projected CAGR of 5.34% over the forecast period.
Market Concentration and Key Players
The global intraosseous access needle market exhibits a moderately concentrated structure, with a small number of leading companies holding the majority market share. Major players include Pyng Medical, Allied Medical, PerSys Medical, Teleflex, and Becton, Dickinson and Company (BD). Teleflex holds over 25% of the North American market with its Arrow EZ‑IO series, while BD, Cook Medical, Teleflex, and PerSys Medical collectively accounted for approximately 70% of global revenue in 2024.
Product Type Segmentation
By product type, the intraosseous device market is segmented into intraosseous infusion sets, intraosseous needles, and others. Disposable intraosseous needles dominate the market with a 66% share. By technology, the market is divided into manual and automatic intraosseous infusion devices; automatic devices are growing rapidly due to ease of operation and high success rates. By patient age group, pediatric patients represent the largest share, accounting for 68.2% of the total market in 2024.
Regional Market Distribution
North America leads the global market, with a total valuation of USD 424.2 million in 2024. This leadership stems from advanced healthcare infrastructure and a high volume of emergency procedures in the region. In the United States, the market grew from USD 365.5 million in 2023 to USD 382.9 million in 2024. Europe follows closely, while the Asia‑Pacific region has emerged as the fastest‑growing market, driven by expanded diagnostic capabilities and rising awareness of early detection.
Market Drivers
The rising demand for rapid vascular access in emergency procedures is the primary growth driver. Hospital data indicates that drug delivery time is reduced by 63% with intraosseous access compared to repeated peripheral intravenous attempts. In urban trauma centers, over 58% of code blue events now include intraosseous access protocols. Pre‑hospital providers report an average first‑attempt IO access success rate of 76%, versus a 49% success rate for peripheral venous access in hypoperfused patients.
Competitive Landscape Analysis
The combined global shipment volume of the top four intraosseous device manufacturers accounts for 48% of the market. In June 2023, Teleflex announced FDA approval of its Arrow EZ‑IO needle for MRI environments, making it the first and only intraosseous needle to receive MR‑Conditional labeling. In October 2024, BD launched a next‑generation intraosseous vascular access system-the only IO device on the market that can be placed after extension tubing connection, and the only system with integrated passive needle‑tip safety features.
